Summary We have examined levels of epidermal growth factor (EGF) and transforming growth factor alpha (TGF-a) in neoplastic and non-neoplastic bladder tissue using a standard radioimmunoassay technique. Tumour samples had much higher TGF-ax levels compared with EGF and TGF-a levels in malignant tissue were significantly higher than in benign bladder samples. There was, in addition, a difference in mean EGF levels from 'normal' bladder samples from non-tumour bearing areas of bladder in patients with bladder cancer compared with 'normal' bladder tissue obtained at the time of organ retrieval surgery. Levels of EGF and TGF-c did not correlate with levels of EGF receptor (EGFR) as determined by a radioligand binding method but levels of TGF-oc >10 ng gm of tumour tissue did correlate with EGFR positivity defined using immunohistochemistry. These data suggest that TGF-a is the likely ligand for EGFR in bladder tumours.
Expression of epidermal growth factor receptors (EGFRs) may have a role in the management of transitional cell carcinoma of the bladder, having prognostic significance in those patients with non-muscle-infiltrative cancers (Neal et al., 1990; Mellon et al., 1995) . EGFRs found in bladder cancers have previously been shown to be functional (Berger et al., 1987; Smith et al., 1989) and although some studies have assessed the effect of EGFR ligands on bladder tumour cell lines (Messing, 1984 (Messing, , 1987 Momose et al., 1991; Kawamata et al., 1993) , few studies have examined for the presence of ligands for the EGFR within the bladder tumour itself. EGF has been examined in tumour tissue of renal and urothelial origin as well as normal tissue using immunocytochemistry (Lau et al., 1988) . Typical granular staining was noted in the cytoplasm of all transitional cell and squamous carcinomas of the bladder. Staining of normal urothelium was limited to superficial cells only. Subjectively, the staining intensity of transitional cell carcinomas correlated inversely with tumour differentiation. In view of the fact that internalised, receptor-bound EGF is known to be rapidly degraded, the results from this immunohistochemical study suggest that there is active synthesis of EGF within the cytoplasm, perhaps being involved in autocrine mechanisms of malignant proliferation.
In an immunohistochemical study we noted that bladder tumours with EGFR expression also stained positively for transforming growth factor alpha (TGF-a), again consistent with an autocrine regulation of growth (Gullick et al., 1991) . The effect of TGF-x on bladder tumour cells has been studied by transfecting NBT-II rat carcinoma cells with a gene encoding human TGF-ac (Gavrilovic et al., 1990) . It was subsequently noted that the cells became motile and vimentin positive and secreted significant levels of a 95 kDa gelatinolytic metalloproteinase. These results suggest that expression of TGF-a in an epithelial tumour cell results in the development of a motile, fibroblast-like phenotype with matrix-degrading potential, which could result in a more aggressive tumour in vivo.
Other studies have looked at EGF levels in the urine of patients with bladder cancer. There appears to be a consensus that the level of EGF in the urine is reduced in patients with bladder tumours of increasing stage with levels rising again following tumour ablation (Kristensen et al., 1988; Fuse et al., 1992) .
The objectives of this study were to quantify levels of EGF and TGF-cx in bladder cancers by biochemical methods and to correlate this information with EGFR levels with the aim of determining whether EGFR ligands were present in levels that might activate the EGFR.
Patients and methods
Seventy-four patients with newly diagnosed bladder cancer, requiring surgical resection or biopsy, were studied. Following cystocopy, examination under anaesthesia, tumour resection and, where indicated, a computerised tomography (CT) scan, tumours were staged by the TNM system (Hermanek and Sobin, 1987) and graded histologically (by a single uropathologist) according to the system described by Bergkvist et al. (1965) . All conceivable measures were taken to ensure samples contained a maximal amount of tumour material. Representative samples of each tumour were carefully collected in the operating theatre by the two surgeons with a major interest in this study. For those patients with Ta and Ti tumours, these vascular tumours have a very high tumour-stroma ratio and very infrequently have areas of tumour necrosis. In addition, the majority of these superficial tumours are exophytic papillary tumours, which are easily identifiable from adjacent tissues. For muscle-invasive tumours necrotic tumour was deliberately avoided when collecting samples. In addition, samples of non-neoplastic bladder were collected from patients undergoing surgery for benign bladder pathology (n = 3) and at the time of multiorgan retrieval surgery (n =4) as well as four samples of 'normal' bladder collected from non-tumourbearing areas of bladder at the time of cystectomy for bladder cancer. Samples of fresh, unfixed bladder tissue were immediately frozen in liquid nitrogen. All tumour samples and seven normal bladder samples were assayed for EGFR and 40 tumours along with seven normal bladder samples were assayed for EGF and TGF-oa.
Radioligand binding assay for EGFR The essential steps of the radioligand binding assay for the detection of EGFR have previously been reported (Sainsbury et al., 1985; Nicholson et al., 1988; Smith et al., 1989 al., 1988) , indicating satisfactory membrane preparation. The supernatant (tumour cystosol) was decanted and stored at -70°C in preparation for estimation of EGF and TGF-a levels by radioimmunoassay (see below). The washed pellet was then resuspended in approximately 3 ml of buffer using a glass -glass homogeniser and stored in 1 ml aliquots at -70°C.
Two-point assay for the EGFR An aliquot of membrane suspension was removed from the -70°C freezer and thawed. Following determination of the protein content using the method of Lowry (1951) , the protein concentration was adjusted to 1 mg ml-' by the addition of buffer.
Reaction tubes were incubated in a waterbath at +26°C for 1 h. The reaction was terminated by the addition of 1 ml of cold buffer. Samples were centrifuged for 5 min at 13 000 r.p.m. using a Microcentaur bench microcentrifuge. After aspiration of the supernatant the membrane pellet was washed with 0.5 ml of buffer, centrifuged for a further 5 min and all the supernatant carefully aspirated. The radioactivity of the pellet was then counted in a gamma-counter. Total binding varied between 0.48% and 9.67% of total counts and non-specific binding varied from 0.41% to 1.14% of total counts. Specific binding was calculated by subtracting nonspecific binding from total binding.
Assay for TGF-a and EGF Extraction of EGF/TGF-a The cytosol, i.e. the supernatant following high-speed centrifugation, was added to twice its volume of ice-cold ethanol (kept on ice), vortexed and immediately centrifuged at 1250 g for 30 min at + 4°C (equivalent to 2500 r.p.m. using a Sorval RC -3B centrifuge). Centrifugation produced a protein residue, while EGF/ TGF-a remained soluble in the supernatant.
The supernatant was decanted into four times its volume of ice-cold ethyl acetate and, as opposed to vortexing, this mixture was left undisturbed at + 4°C for a minimum of 16 h. Ethyl acetate allows separation of an aqueous phase containing insoluble growth factors. After 16 h the small aqueous phase, visible at the base of the flask, was collected by carefully aspirating the organic phase with a tap waterpump leaving approximately 0.5 ml in the flask. The flask was washed with 2 x 1 ml washes of 1 M acetic acid, collecting the washes in a small container in preparation for lyophilisation. The contents of the container were then frozen by dipping in liquid nitrogen, immediately before lyophilisation in a freeze drier.
Lyophilisation of samples This was performed overnight in a freeze drier (Edwards EF4 Modulyo; Temperature, -70°C, Pressure, 0.1 atm), containing sodium hydroxide for the adsorption of acetic acid and carbon dioxide. Once dry, the lyophilised samples were stored at -20°C until analysed.
Radioimmunoassay for EGF and TGF-a Immediately before analysis samples were warmed to + 4°C and reconstituted in 1 ml of assay buffer (40 mM phosphate buffer, pH 7.2).
TGF-a and EGF in bladder cancer JK Mellon et al M 655 Reconstituted samples were constantly kept on ice. The method used for determining tissue levels of EGF and TGF-a was similar to the method described by Gregory et al. (1989) . Optimal assay conditions were defined before the analysis of samples (data not included). Parameters tested were: primary antibody dilution, primary antibody incubation time, secondary antibody incubation time, incubation temperature and effect of different buffer solutions. In addition, the effect of preincubation was assessed. The delayed addition of labelled ligand to the assay system is known to improve the ability of a radioimmunoassay to detect very low concentrations of unlabelled ligand (Samols and Bilkus, 1964 TGF-a/EGF and EGFR There was no relationship between TGF-a levels and EGF levels (Figure 4) . Nor was there a relationship between EGF levels and EGFR ( Figure 5 ) or between TGF-a levels and EGFR content ( Figure 6 ) when comparing results from the radioimmunoassay for EGF/ TGF-a with results from the radioligand binding assay for EGFR. However, the majority of tumours (n = 32) were also assessed for EGFR using an immunohistochemical method There was a positive correlation between EGFR positivity as defined by immunohistochemistry and a TGF-ax level of greater than 10 ng g-' of tumour tissue (Table IV) . Attempts have been made by workers in other institutions to exploit EGF receptor overexpression by certain tumours by conjugating cytotoxic agents with EGF or TGF-a (Chaudhary et al., 1987; Sarosdy et al., 1992) . Conjugation of such agents with receptor ligand rather than with large monoclonal antibodies to the receptor has a theoretical advantage in that tumour tissue penetration should be better. Most recently a hybrid protein (TP-40) consisting of TGF-a fused to a segment of pseudomonas exotoxin-A protein has been shown to selectively bind tissues rich in EGFR. In studies using the bladder carcinoma cell lines, 5637, J82, RT4, Scaber, T-24, MBT-2 and TCC-SUP, TP-40 has been shown to have a significant growth-inhibitory effect (Sarosdy et al., 1993) .
